DCAF16

Across TCGA pan-cancer cohorts, DCAF16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCAF16 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DCAF16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCAF16 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where DCAF16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.232	0.889	.012	17	view →
PDAC	OS	Tertile	All	0.793	0.932	.015	6	view →
CCRCC	DFS	Tertile	All	0.890	0.198	.024	5	view →
LSCC	OS	Tertile	All	0.716	0.909	.016	4	view →
GBM	OS	Quartile	All	0.557	0.329	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCAF16–LUAD (DFS)

Open the LUAD breakdown →